Literature DB >> 17461312

Immunonutrition in elective gastrointestinal surgery patients.

H Helminen1, M Raitanen, J Kellosalo.   

Abstract

BACKGROUND: Previous trials have shown that perioperative immunonutrition could protect patients from infectious complications after gastrointestinal cancer operations. The purpose of this study was to determine whether perioperative immunonutrition decreases postoperative morbidity, especially infection complications, mortality and length of hospital stay in patients undergoing major gastrointestinal tract surgery.
METHODS: One hundred patients with a planned elective operation for benign or malignant gastrointestinal illness were randomized into two groups: group 1) oral supplementation for five days before and five days after surgery with 900 mL/day of a formula enriched with arginine, gamma-3-fatty acid and RNA + liquid diet ad libitum on one and two postoperative day and then solid food (immunonutrition group; n = 50) or group 2) no artificial nutrition before and after surgery, on one and two postoperative day intravenous solution of 5% glucose and electrolytes and then normal diet (conventional group; n = 50).
RESULTS: The groups were comparable for all key baseline and surgical characteristics. There were nine (18%) infectious complications in both groups. Overall complication rates were 28% (n = 14) in the immunonutrition group and 24% (n = 12) in the conventional group. No significant difference between the groups was found in complication rates, mortality or length of hospital stay.
CONCLUSION: Routine perioperative immunonutrition to the patients undergoing major gastrointestinal surgery is not beneficial.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17461312     DOI: 10.1177/145749690709600109

Source DB:  PubMed          Journal:  Scand J Surg        ISSN: 1457-4969            Impact factor:   2.360


  8 in total

1.  Arginine-supplemented enteral nutrition.

Authors:  Jutta Huebner; Ralph Muecke
Journal:  J Cancer Res Clin Oncol       Date:  2014-02-13       Impact factor: 4.553

2.  Perioperative immunonutrition in normo-nourished patients undergoing laparoscopic colorectal resection.

Authors:  Pedro Moya; Elena Miranda; Leticia Soriano-Irigaray; Antonio Arroyo; Maria-Del-Mar Aguilar; Marta Bellón; Jose-Luis Muñoz; Fernando Candela; Rafael Calpena
Journal:  Surg Endosc       Date:  2016-03-02       Impact factor: 4.584

Review 3.  Appropriate protein and specific amino acid delivery can improve patient outcome: fact or fantasy?

Authors:  Christy M Lawson; Keith R Miller; Vance L Smith; Stephen A McClave
Journal:  Curr Gastroenterol Rep       Date:  2011-08

4.  Malnutrition, frailty, and sarcopenia in pancreatic cancer patients: assessments and interventions for the pancreatic surgeon.

Authors:  Noah S Rozich; Caitlin E Jones; Katherine T Morris
Journal:  Ann Pancreat Cancer       Date:  2019-03-11

5.  Perioperative immunonutrition in surgical cancer patients: a summary of a decade of research.

Authors:  Stanislaw Klek; Piotr Szybinski; Kinga Szczepanek
Journal:  World J Surg       Date:  2014-04       Impact factor: 3.352

Review 6.  Impact of oral preoperative and perioperative immunonutrition on postoperative infection and mortality in patients undergoing cancer surgery: systematic review and meta-analysis with trial sequential analysis.

Authors:  F Buzquurz; R D Bojesen; C Grube; M T Madsen; I Gögenur
Journal:  BJS Open       Date:  2020-06-23

Review 7.  Sterile post-traumatic immunosuppression.

Authors:  Md Nahidul Islam; Benjamin A Bradley; Rhodri Ceredig
Journal:  Clin Transl Immunology       Date:  2016-04-29

8.  Perioperative Standard Oral Nutrition Supplements Versus Immunonutrition in Patients Undergoing Colorectal Resection in an Enhanced Recovery (ERAS) Protocol: A Multicenter Randomized Clinical Trial (SONVI Study).

Authors:  Pedro Moya; Leticia Soriano-Irigaray; Jose Manuel Ramirez; Alessandro Garcea; Olga Blasco; Francisco Javier Blanco; Carlo Brugiotti; Elena Miranda; Antonio Arroyo
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.